Dr. Rajani explains the reasons we develop a double chin are multi-factorial--but mainly as we…
Kybella in the News – Portland, Oregon
Double chin is a common issue that affects both men and woman starting at an early age. Accumulation of fat tissue under the chin is what causes a double chin. In the past, expensive surgical procedures like liposuction and injections from Botox were used to get rid of double chin. A breakthrough for the treatment of double chin has arrived in the form of Kybella, a drug that has been approved by the Food and Drug Authority (FDA) for the treatment of unwanted double chin. It is a product of Kythera Biopharmaceuticals, Inc. that has few side effects and a great success rate.
20 clinical trials were performed to test Kybella’s efficacy before its launch. More than 2,600 patient from around the world participated in these trials. Over 1600 of these patients were treated with Kybella with the target to get rid of the adipose fat tissue around the chin area. The figures that the trial produced were staggering. 68.2 percent of the test subjects came back with positive results and responded to injections with Kybella. These patients reported both a reduction of fat under the chin as well as an improved look in their aesthetic appearance.
Several side effects of the Kybella also showed with these studies. The study was conducted by giving 50% of the subjects Kybella and the other 50% a placebo. 96% of the subjects who were given Kybella noticed site reactions at the point of injection. These reactions include erythema, swelling, numbness, hematoma formation, induration, paresthesia, nodule formation, pruritus, skin tightness, nerve injury, local warmth. 8% of subjects complained of headache. About 3% of them reported oropharyngeal pain. 2% of them experienced nausea and another 2% had difficulty in swallowing.
No reliable data information shows Kybella being safe for use in pregnant women and women who are lactating. It has is no currently available for children under 18 and adults over 65. Approval for these age groups would require further trials in the future and approval by FDA.
Two randomized controlled, double blinded trials were held to assess the effectiveness of Kybella for the treatment of double chin in a group aged 19 to 65. Significant reduction in the amount of submental fat was reported in subjects who were given Kybella as compared to those who were given the placebo. These trials, thus, proved the effectiveness of Kybella in both decreasing the submental convexity as well as enhancing the overall appearance.
For more information on Kybella and how to treat your double chin, contact Dr. Rajani at 503.303.8313 or email firstname.lastname@example.org.